While the EGFRxHER2 heterodimer T-BsAb could ablate EGFR+HER2+ double-positive pancreatic tumors, deletion of either EGFR or HER2 completely abrogated antitumor efficacy. This evidence concerns the gene EGFR and pancreatic neoplasm.